Synthetic Biology

Can Armored CAR T Cells Defeat Solid Tumor Defenses?
Research & Development Can Armored CAR T Cells Defeat Solid Tumor Defenses?

Ivan Kairatov is a seasoned Biopharma expert with a rich background in research and development, specializing in the cutting edge of oncological innovation. In this discussion, we explore the breakthrough development of armored CAR-T cells designed to dismantle the physical and chemical barriers of

CGT Catapult Forms Board to Scale Advanced Therapies
Biotech & Bioprocessing CGT Catapult Forms Board to Scale Advanced Therapies

The medical community has finally reached a point where the ability to edit the human genome and engineer immune cells is no longer a futuristic aspiration but a clinical reality. However, a significant disconnect remains between these scientific triumphs and the ability to deliver such cures to

Can Antibody Engineering Finally Defeat Glioblastoma?
Biotech & Bioprocessing Can Antibody Engineering Finally Defeat Glioblastoma?

The relentless progression of oncology over the past several decades has fundamentally altered the prognosis for many once-terminal cancers, yet glioblastoma remains a stubborn outlier in this narrative of medical triumph. While the integration of immune checkpoint inhibitors and targeted

Can MULTI-evolve Revolutionize Protein Engineering Efficiency?
Tech & Innovation Can MULTI-evolve Revolutionize Protein Engineering Efficiency?

Ivan Kairatov is a leading expert in biopharmaceutical innovation with a distinguished career in research and development, specializing in the intersection of artificial intelligence and synthetic biology. As a key contributor to the development of high-throughput protein engineering frameworks, he

EU Approves GSK’s Twice-Yearly Asthma and Sinus Treatment
Biotech & Bioprocessing EU Approves GSK’s Twice-Yearly Asthma and Sinus Treatment

Managing severe, persistent respiratory conditions often feels like a relentless battle, with frequent treatments and the constant threat of debilitating flare-ups dictating the rhythm of daily life. For millions, conditions like severe asthma and chronic rhinosinusitis with nasal polyps represent

Gazyva Succeeds in Phase III Autoimmune Kidney Disease Trial
Biotech & Bioprocessing Gazyva Succeeds in Phase III Autoimmune Kidney Disease Trial

A groundbreaking Phase III clinical trial has revealed that the therapy Gazyva (obinutuzumab) demonstrates superior efficacy over the current standard-of-care treatment, tacrolimus, for adults grappling with primary membranous nephropathy. The MAJESTY trial’s success represents a significant

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later